An­thos' blood thin­ner cuts the risk of bleed­ing amid race to de­vel­op safer an­ti­co­ag­u­lants

PHILADEL­PHIA — An an­ti­co­ag­u­lant from An­thos Ther­a­peu­tics sub­stan­tial­ly cut the risk of bleed­ing com­pared to Xarel­to in a mid-stage safe­ty study.

The An­thos drug is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER